Timothy Sullivan - Jan 17, 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Financial Officer
Signature
/s/s David Watson, attorney-in-fact for Timothy Sullivan
Stock symbol
APLS
Transactions as of
Jan 17, 2025
Transactions value $
-$51,828
Form type
4
Date filed
1/21/2025, 04:11 PM
Previous filing
Jan 14, 2025
Next filing
Jan 23, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale -$51.8K -1.73K -1.96% $29.96 86.4K Jan 17, 2025 Direct F1
transaction APLS Common Stock Award $0 +45.9K +53.18% $0.00 132K Jan 21, 2025 Direct F2
holding APLS Common Stock 70.4K Jan 17, 2025 The Timothy E Sullivan Irrevocable Trust of 2023 F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2025.
F2 This represents a Restricted Stock Unit award granted on January 21, 2025 that vest 25% annually over four years from grant date subject to continued service.
F3 The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.